Concurrently, valsartan orchestrates multi-pathway regulation by targeting genetic networks involved in RAS hyperactivation, AGE-RAGE crosstalk, TGF-β signaling, and PI3K-Akt axis dysregulation, thereby mitigating renal fibrosis and tubular injury [155]. The gene discussed is AKT1; the disease is renal fibrosis.